Mechanisms of resistance to antiviral agents;Mecanismos de resistencia a los antivirales en el grupo herpesvirus

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 15, Issue 6, 1997, Pages 329-334

  Reina, Jordi ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; PENCICLOVIR;

CYTOMEGALOVIRUS; DRUG RESISTANCE; HERPES; HERPES SIMPLEX VIRUS; HERPES VIRUS; NONHUMAN; REVIEW; VARICELLA ZOSTER VIRUS;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; DRUG RESISTANCE, MICROBIAL; FOSCARNET; GANCICLOVIR; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 3, HUMAN; HUMANS; SIMPLEXVIRUS; VIRUS REPLICATION;

EID: 0030849249     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Roizman B, Whitley RJ, López C. The human herpesviruses. Nueva York: Raven Press, 1993.
2. Glaser R, Jones JF. Herpesvirus infections. Nueva York: Marcel Dekker Inc., 1994.
3. a ed). Filadelfia: Lippincott-Raven, 1996; 2.343-2.396.
4. a ed.). Filadelfia: Lippincott-Raven, 1996; 2.221-2.230.
5. a ed.) Nueva York: Plenum Medical Press, 1994; 379-396.
6. a ed.) Filadelfia: Lippincott-Raven, 1996; 431-466.
7. Chatis PA, Crumpacker CS. Resistance of herpesvirus to antiviral drugs. Antimicrob Agents Chemother 1992; 36: 1.589-1.595.
8. Coen DM. The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy. Antiviral Res 1991; 15: 287-300.
9. Freifeld AG, Ostrove JM. Resistance of viruses to antiviral drugs. Annu Rev Med 1991; 42: 247-259.
10. Whitley RJ, Gnann JW. Acyclovir a decade later. N Engl J Med 1992; 327: 782-789.
11. Torres-Cisneros J. Valaciclovir: una nueva opción en el tratamiento antiherpético. Rev Esp Quimioterap 1996; 9: 121-125.
12. Valenciano L. Nuevos antiherpéticos. Rev Esp Quimioterap 1995; 8: 275-278.
13. Fyfe JA, Keller PM, Furman PA, Miller RA, Elion GB, Elion GB. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(-2-hydroxyethoxymethyl) guanine. J Biol Chem 1978; 253: 8.721-8.927.
14. Elion GB. Mechanism of action and selectivity of acyclovir. Am J Med 1982; 73: (Supl 1A): 7-13.
15. Elion FB. The biochemistry and mechanism of action of acyclovir. J Antimicrob Chemother 1983; 12 (Supl B): 9-17.
16. Derse D, Chang YC, Furman PA, St. Clair MH, Elion GB. Inhibition of purified human and herpes simplex virus-induced DNA polymerase by 9-(2-hydroxyethoxymethyl) guanine triphosphate. Effects on primer-template function. J Biol Chem 1981; 256: 11.447-11.451.
17. Furman PA, St. MH, Spector T. Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase. J Biol Chem 1984; 259: 9.575-9.579.
18. Reardon JE, Spector T. Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J Biol Chem 1989; 264: 7.405-7.411.
19. Furman PA, St. Clair PA, Fyfe JA, Rideout JL, Keller PM, Elion GB. Inhibition of herpes simplex virus induced DNA polymerase activity and viral DNA replication of 9-(2-hydroxyethoxymethyl) guanine and its triphosphate. J Virol 1979; 32: 72-77.
20. Field AK, Biron KK. The end of inocence revisited: resistance of herpesvirus to antiviral drugs. Clin Microbiol Rev 1994; 7: 1-13.
21. Kimberlin DW, Whitley RJ. Antiviral resistance: mechanisms, clinical significance and future implications. J Antimicrob Chemother 1996; 37: 403-421.
22. Coen DM, Schaffer PA. Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proc Natl Acad Sci USA 1980; 77: 2.265-2.269.
23. Schnipper LE, Crumpacker CS. Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci. Proc Natl Acad Sci USA 1980; 77: 2.270-2.273.
24. Hill EL, Hunter GA, Ellis MN. In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1991; 35: 2.322-2.328.
25. Darby G, Field HJ, Salisbury SA. Altered substrate specificity of herpes simplex virushymidine kinase confers acyclovir-resistance. Nature 1981; 289: 81-83.
26. Ellis MN, Keller PM, Fyfe JA, Martin JL, Rooney JF, Straus SE et al. Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity. Antimicrob Agents Chemother 1987; 31: 1.117-1.125.
27. Chatis PA, Crumpacker CS. Analysis of the thymidine kinase gene from clinically isolated acyclovir-resistant herpes simplex viruses. Virology 1991; 180: 793-797.
28. Kosh RG, Hill EL, Tigges M, Straus SE. Recurrent acyclovir-resistant genital herpes in an immunocompetent host. N Engl J Med 1993; 329: 1.777-1.782.
29. Collins P, Larder BA, Oliver NM, Kemp S, Smith IW, Darby G. Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir. J Gen Virol 1989; 70: 375-382.
30. Sacks SL, Wanklin RJ, Reece DE, Hicks KA, Tyler KL, Coen DM. Progresive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity? Ann Intern Med 1989; 111: 893-899.
31. Hwang CBC, Ruffner KL, Coen DM. A point mutation within a distinct conserved region of the herpes simplex virus DNA polymerase gene confers drug resistance. J Virol 1992; 66: 1.774-1.776.
32. Gibbs JS, Chiou HC, Bastow KF, Cheng YC, Coen DM. Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition. Proc Natl Acad Sci USA 1988; 85: 6.672-6.676.
33. Marcy AI, Yager DR, Coen DM. Isolation and characterization of herpes simplex virus mutants containing engineered mutations at the DNA polymerase locus. J Virol 1990; 64: 2.208-2.216.
34. Reusser P. Herpesvirus resistance to antiviral drugs: a review of the mechanism, clinical importance and therapeutic options. J Hosp Infect 1996; 33: 235-248.
35. Safrin S, Phan L. In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus. Antimicrob Agents Chemother 1993; 37: 2.241-2.243.
36. Talarico CL, Phelps WC, Biron KK. Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. J Virol 1993; 67: 1.024-1.033.
37. Nugier F, Colin JN, Aymard M, Langlois M. Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey. J Med Virol 1992; 36: 1-12.
38. Englund JA, Zimmermann ME, Swierkosz EM, Goodmann JL, Scholl DR, Balfour HH. Herpes simplex virus to acyclovir. A study in a tertiary care center. Ann Intern Med 1990; 112: 416-422.
39. Nyquist AC, Rotbart HA, Cotton M, Robinson C, Weinberg A, Hayward AR et al. Acyclovir-resistant neonatal herpes simplex virus infection of the larynx. J Pediatr 1994; 124: 967-971.
40. Safrin S, Kemmerly S, Plotkin B, Smith T, Weissbach N, De Veranez D et al. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis 1994; 169: 193-196.
41. a ed.). Filadelfia: Lippincott-Raven, 1996; 2.547-2.585.
42. Boivin G, Edelman CK, Pedneault L, Talarico CL, Biron KK, Balfour HH. Phenotypic and genotypic characterization of acyclovir resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis 1994; 170: 68-75.
43. Lacey SF, Suzutani T, Powell KL, Purifory DJM, Honess RW. Analysis of mutations in the thymidine kinase genes of drug-resistant varicella zoster virus populations using the polymerase chain reaction. J Gen Virol 1991; 72: 623-630.
44. Gaillard R, Short S, Gaillard M, Stanat S, Biron K. Sequence alterations in the DNA polymerase genes of VZV strains selected for in vitro resistance to acyclovir or phosphonoacetic acid. [resumen 154]. XV International Herpesvirus Workshop, 1990.
45. Stanat SC, Talarico CL, Safrin S, Biron KK. Sequential varicella zoster virus isolates from an AIDS patients: phenotypic and genetic evidence for evolution of drug resistance at the thymidine kinase and DNA polimerase loci. [resumen 16]. XVII International Herpesvirus Workshop, 1992.
46. Pahwa S, Biron K, Lim W, Swenson P, Kaplan MH, Sadick N et al. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA 1988; 260: 2.879-2.882.
47. Safrin S, Berger TG, Gulson I, Wolfe PR, Wofsy CB, Mills J et al. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella zoster virus infection. Ann Intern Med 1991; 115: 19-21.
48. Fillet AM, Visse B, Caumes E, Dumont B, Gentilini M, Huraux JM. Foscarnet-resistant multidermatomal zoster in a patient with AIDS. Clin Infect Dis 1995; 21: 1.348-1.349.
49. Stanat SC, Reardon JE, Erice A, Jordan MC, Drew WL, Biron KK. Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistant to ganciclovir. Antimicrob Agents Chemother 1991; 35: 2.191-2.197.
50. Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992; 358: 160-162.
51. Crumpacker CS. Ganciclovir. N Engl J Med 1996; 335: 721-729.
52. Baldanti F, Silini E, Sarasini A, Talarico CL, Stanat SC, Biron KK et al. A three nucleotide-deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. J Virol 1995; 69: 796-800.
53. Chou S, Erice A, Jordan MC, Vercellotti GM, Michels KR, Talarico CL et al. Analysis of the UL97 phosphostransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 1995; 171: 576-583.
54. Wolf DG, Smith IL, Lee DJ, Freemen WR, Flores-Aguilar M, Spector SA. Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J Clin Invest 1995; 95: 257-263.
55. Lurain NS, Thompson KD, Holmes EW, Read GS. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J Virol 1992; 66: 7.146-7.152.
56. Sullivan V, Viron KK, Talarico C, Stanat SC, Davis M, Pozzi LM et al. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob Agents Chemother 1993; 37: 19-25.
57. Tatarowicz WA, Lurain NS, Thompson KD. A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. J Infect Dis 1992; 166: 904-907.
58. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH, Jordan MC. Progressive disease due to ganciclovir resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989; 320: 289-293.
59. Drew WL, Miner RC, Busch DF, Follansbee SE, Gullett J, Mehalko SG et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991; 163: 716-719.
60. Slavin MA, Bindra RR, Gleaves CA, Pettinger MB, Bowden RA. Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients. Antimicrob Agents Chemother 1993; 37: 1.360-1.363.
61. Leport C, Puget S, Pepin JM. Cytomegalovirus resistant to foscarnet: clinicovirologic correlation in a patient with human immunodeficiency virus. J Infect Dis 1993; 168: 1.329-1.330.
62. Drew WL, Miner RC, Crager M, Stempien MJ. Does resistance to ganciclovir develop in a patients receiving prophylactic drug? [resumen H135]. ICAAC. American Society for Microbiology, 1995.
63. Dieterich DT, Poles MA, Lew EA, Mendez PE, Murphy R, Addessi A et al. Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. J Infect Dis 1993; 167: 1.184-1.188.